An FDA panel is scheduled to scrutinize Nirsevimab, a long-acting respiratory syncytial virus (RSV) F protein inhibitor monoclonal antibody for intramuscular use, on June 8, 2023.The proposed indication of Nirsevimab is prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.Nirsevimab is being jointly developed and commercialized by AstraZeneca in collaboration with Sanofi.The drug, under the brand name Beyfortus, was approved in the European Union, last November, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.AZN closed Friday’s (May 26, 2023) trading at $72.52, up 1.02%.